Imunon, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
997 LENOX DRIVE, LAWRENCEVILLE, NJ, 08648
Mailing Address
997 LENOX DRIVE, LAWRENCEVILLE, NJ, 08648
Phone
(609) 896-9100
Fiscal Year End
1231
EIN
521256615
Financial Overview
FY2025
$5.47M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 23, 2026 | View on SEC |
| 424B5 Prospectus supplement | March 23, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 17, 2026 | View on SEC |
| 8-K Current report of material events | February 5, 2026 | View on SEC |
| 3 Initial insider ownership report | January 20, 2026 | View on SEC |
| 8-K Current report of material events | January 7, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
Annual Reports
10-K
March 31, 2026
- Lead drug candidate IMNN-001 showed significant survival benefits in Phase 2 ovarian cancer trials.
- FDA has granted 'Fast Track' status to IMNN-001, accelerating the path to Phase 3 testing.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.